Search Results - "KRAUT, Eric H"

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein by HOFMEISTER, Craig C, XIAOXIA YANG, JIA JI, SCHAAF, Larry J, BENSON, Don M, KRAUT, Eric H, HICKS, William J, CHAN, Kenneth K, CHEN, Ching-Shih, FARAG, Sherif S, GREVER, Michael R, BYRD, John C, PICHIORRI, Flavia, PHELPS, Mitch A, PING CHEN, ROZEWSKI, Darlene M, JOHNSON, Amy J, LEE, Seungsoo, ZHONGFA LIU, GARR, Celia L, HADE, Erinn M

“…Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical…”
Get full text

Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders by LIN, Thomas S, BLUM, Kristie A, SCHAAF, Larry J, GREVER, Michael R, BYRD, John C, BETH FISCHER, Diane, MITCHELL, Sarah M, RUPPERT, Amy S, PORCU, Pierluigi, KRAUT, Eric H, BAIOCCHI, Robert A, MORAN, Mollie E, JOHNSON, Amy J

“…Flavopiridol downmodulates antiapoptotic proteins associated with resistance to fludarabine and rituximab and is effective against p53-mutated chronic…”
Get full text

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020 by Becker, Pamela Sue, Griffiths, Elizabeth A, Alwan, Laura M, Bachiashvili, Kimo, Brown, Anna, Cool, Rita, Curtin, Peter, Dinner, Shira, Gojo, Ivana, Hicks, Ashley, Kallam, Avyakta, Kidwai, Wajih Zaheer, Kloth, Dwight D, Kraut, Eric H, Landsburg, Daniel, Lyman, Gary H, Miller, Ryan, Mukherjee, Sudipto, Patel, Shiven, Perez, Lia E, Poust, Adam, Rampal, Raajit, Rosovsky, Rachel, Roy, Vivek, Rugo, Hope S, Shayani, Sepideh, Vasu, Sumithira, Wadleigh, Martha, Westbrook, Kelly, Westervelt, Peter, Burns, Jennifer, Keller, Jennifer, Pluchino, Lenora A

“…Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic…”
Get more information

An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura by Cataland, Spero R., Jin, Ming, Ferketich, Amy K., Kennedy, Melanie S., Kraut, Eric H., George, James N., Wu, Haifeng M.

“…Summary We present the results of two consecutively performed cohort studies that evaluated the clinical effects of corticosteroids or ciclosporin as an…”
Get full text

A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors by BEKAII-SAAB, Tanios S, JING LIU, CHAN, Kenneth K, BALCERZAK, Stanley P, IVY, Percy S, GREVER, Michael R, KRAUT, Eric H

“…Purpose: Oxaliplatin and paclitaxel are widely used in treating solid tumors. We designed a phase I study with the purpose of determining the maximal tolerated…”
Get full text

Experience With Pre-procedural Hemostatic Medications versus Platelet Transfusion in Patients With Platelet Storage Pool Deficiency by Lundy, Katharine A., Rabatin, Abigail, Davidson, Erica R., Li, Junan, Snider, Melissa J., Kraut, Eric H.

“…Background Storage pool deficiency (SPD) is a rare bleeding disorder characterized by reduction in the number of delta granules within platelets, interfering…”
Get full text

A Case Report of Siblings with Dystonia: A Potential Link Between DYT11 Mutation and Platelet Dysfunction by Damante, Mark, Ganguly, Ranjit, Huntoon, Kristin, Kraut, Eric, Deogaonkar, Milind

“…Myoclonus-dystonia syndrome (MDS) is an autosomal dominant disorder due to a mutated epsilon-sarcoglycan gene (SGCE) at the dystonia 11 (DYT11) locus on…”
Get full text

Cancer- and chemotherapy-induced anemia by Rodgers, 3rd, George M, Becker, Pamela Sue, Blinder, Morey, Cella, David, Chanan-Khan, Asher, Cleeland, Charles, Coccia, Peter F, Djulbegovic, Benjamin, Gilreath, Jeffrey A, Kraut, Eric H, Matulonis, Ursula A, Millenson, Michael M, Reinke, Denise, Rosenthal, Joseph, Schwartz, Rowena N, Soff, Gerald, Stein, Richard S, Vlahovic, Gordana, Weir, 3rd, Alva B

“…Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care…”
Get more information

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer by SAAD, Everardo D, KRAUT, Eric H, HOFF, Paulo M, MOORE, Dennis F, JONES, Donnah, PAZDUR, Richard, ABBRUZZESE, James L

“…Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We…”
Get full text

A phase I trial of flavopiridol in relapsed multiple myeloma by Hofmeister, Craig C., Poi, Ming, Bowers, Mindy A., Zhao, Weiqiang, Phelps, Mitch A., Benson, Don M., Kraut, Eric H., Farag, Sherif, Efebera, Yvonne A., Sexton, Jennifer, Lin, Thomas S., Grever, Michael, Byrd, John C.

“…Purpose Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and…”
Get full text

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer by Layman, Rachel M., Ruppert, Amy S., Lynn, Melinda, Mrozek, Ewa, Ramaswamy, Bhuvaneswari, Lustberg, Maryam B., Wesolowski, Robert, Ottman, Susan, Carothers, Sarah, Bingman, Anissa, Reinbolt, Raquel, Kraut, Eric H., Shapiro, Charles L.

“…Purpose Triple negative breast cancers (TNBC) frequently have high epidermal growth factor receptor (EGFR) expression and are sensitive to DNA-damaging agents…”
Get full text

Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long‐term follow‐up with serial analysis of ADAMTS13 activity by Cataland, Spero R., Jin, Ming, Lin, Shili, Kennedy, Melanie S., Kraut, Eric H., George, James N., Wu, Haifeng M.

“…Summary We hypothesized that ciclosporin (CSA) as adjunct to plasma exchange (PE) improves the efficacy of PE in idiopathic thrombotic thrombocytopenic purpura…”
Get full text

Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer by Ramaswamy, Bhuvaneswari, Mrozek, Ewa, Kuebler, John Philip, Bekaii-Saab, Tanios, Kraut, Eric H.

“…Summary Purpose : Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. We conducted a…”
Get full text

Myocardial Infarction in Sickle Cell Disease: Use of Translational Imaging to Diagnose an Under-Recognized Problem by Chacko, Paul, Kraut, Eric H., Zweier, Jay, Hitchcock, Charles, Raman, Subha V.

“…Sickle cell disease (SCD) is an inherited disorder in which microvascular occlusion causes complications across multiple organ systems. The precise incidence…”
Get full text

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia by Marcucci, Guido, Byrd, John C., Dai, Guowei, Klisovic, Marko I., Kourlas, Peter J., Young, Donn C., Cataland, Spero R., Fisher, Diane B., Lucas, David, Chan, Kenneth K., Porcu, Pierluigi, Lin, Zhong-Pin, Farag, Sherif F., Frankel, Stanley R., Zwiebel, James A., Kraut, Eric H., Balcerzak, Stanley P., Bloomfield, Clara D., Grever, Michael R., Caligiuri, Michael A.

“…Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia and has been associated with unfavorable clinical outcome. We…”
Get full text

A phase I study of topotecan and gemcitabine in advanced solid tumors by Serna, Derek S., Bekaii-Saab, Tanios, Kraut, Eric H.

“…Summary Purpose Gemcitabine and topotecan are commonly used anti-tumor agents with a wide spectrum of activity in vitro and in vivo. A phase I trial of a…”
Get full text

Bleeding and bruising: a diagnostic work-up by Ballas, Michael, Kraut, Erich H

“…Primary care physicians are often asked about easy bruising, excessive bleeding, or risk of bleeding before surgery. A thorough history, including a family…”
Get full text

Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia by Jones, Jeffrey A., Kraut, Eric H., Deam, Deidre, Byrd, John C., Grever, Michael R.

Get full text

Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura by Cataland, Spero R., Yang, Shang-bin, Witkoff, Leslie, Kraut, Eric H., Lin, Shili, George, James N., Wu, Haifeng M.

“…Objective:  Approximately 40% of idiopathic thrombotic thrombocytopenic purpura (TTP) patients will suffer an exacerbation (recurrence of TTP within 30 d after…”
Get full text

Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN) by Kraut, Eric H., Rhoades, Christopher, Zhang, Yilong, Cheng, Hao, Aimiumu, Josephine, Chen, Ping, Lang, James, Young, Donn C., Agrawal, Amit, Dancey, Janet, Chan, Kenneth K., Grever, Michael R.

“…Purpose This phase I study determined the maximal-tolerated dose, dose-limiting toxicities, pharmacokinetics, and recommended dose of erlotinib with docetaxel…”
Get full text